SNX 2112 | PF-04928473

規(guī)格	庫存	目錄價	會員專享價	數(shù)量
5 mg	3-5days	￥668.00	登錄后可見	- +
10 mg	3-5days	￥998.00	登錄后可見	- +
50 mg	3-5days	￥2860.00	登錄后可見	- +

規(guī)格

庫存

目錄價

會員專享價

數(shù)量

5 mg

3-5days

￥668.00

登錄后可見

- +

10 mg

3-5days

￥998.00

登錄后可見

- +

50 mg

3-5days

￥2860.00

登錄后可見

- +

基本信息

英文名稱	SNX 2112 \| PF-04928473
中文名稱	SNX 2112 \| PF-04928473
CAS號	908112-43-6
分子式	C23H27F3N4O3
分子量	464.48
外觀	White to off-white powder
儲存條件	Store in a dry and dark sealed container, short-term (weeks to months) storage at 0-4 ℃, long-term (months to years) storage at -20 ℃.

產(chǎn)品詳情

SNX-2112, also known as PF 04928473, is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGFR, and AKT as well as abrogation of Ras/Raf/MEK/MAPK and PI3K/AKT signaling, followed by complete cell cycle arrest.

相關(guān)文獻

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.

PMID: 18172276 PMCID: PMC3203688 DOI: 10.1158/1078-0432.CCR-07-1667

Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.

PMID: 19552433 DOI: 10.1021/jm900230j

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

PMID: 18948577 PMCID: PMC2630270 DOI: 10.1182/blood-2008-04-151928

Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.

PMID: 27959508 PMCID: PMC5568423 DOI: 10.1021/acschembio.6b00747